Lung disease treatment approved by NICE

NICE has approved the use of nintedanib (Ofev) on the NHS in patients with idiopathic pulmonary fibrosis, provided the following conditions are met:

Further information
NICE technology appraisal TA379

  • the patient has a forced vital capacity (FVC) between 50% and 80% of predicted
  • the discount agreed in the patient access scheme is honoured by the manufacturer
  • treatment is stopped if there is a confirmed decline in percent predicted FVC of 10% or more in any 12-month period.

The recommendation to discontinue nintedanib in the event of disease progression was deemed to improve cost-effectiveness by minimising continued treatment when the drug is no longer effective. The 10% threshold was obtained from a similar appraisal of pirfenidone.

Nintedanib targets tyrosine kinases involved in pulmonary fibrosis. It is thought to block signalling pathways responsible for fibrotic processes, and may reduce disease progression by slowing the decline of lung function. 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases